LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Aktien・Erasca Inc

Erasca Inc

Geschlossen

13.4 4.44

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.22

Max

13.41

Schlüsselkennzahlen
By Trading Economics
Einkommen	-154M -183M
EPS	-0.6
Angestellte	103
EBITDA	-5.3M -37M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+63.17% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	10. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	476M 3.7B
Vorheriger Eröffnungskurs	8.96
Vorheriger Schlusskurs	13.4

Erasca Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Juni 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9. Juni 2026, 23:45 UTC

Akquisitionen, Fusionen, Übernahmen

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9. Juni 2026, 23:44 UTC

Akquisitionen, Fusionen, Übernahmen

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9. Juni 2026, 23:44 UTC

Akquisitionen, Fusionen, Übernahmen

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9. Juni 2026, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9. Juni 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9. Juni 2026, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9. Juni 2026, 22:05 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9. Juni 2026, 22:05 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung: Additional Investment Makes It Largest Shareholder in Element

9. Juni 2026, 22:05 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9. Juni 2026, 20:51 UTC

Ergebnisse

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. Juni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Juni 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9. Juni 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9. Juni 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9. Juni 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9. Juni 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9. Juni 2026, 18:52 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9. Juni 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9. Juni 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9. Juni 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9. Juni 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9. Juni 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9. Juni 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. Juni 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Juni 2026, 16:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

9. Juni 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9. Juni 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Peer-Vergleich

Kursveränderung

Erasca Inc Prognose

Kursziel

By TipRanks

63.17% Vorteil

12-Monats-Prognose

Durchschnitt 21 USD 63.17%

Hoch 30 USD

Tief 12 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Erasca Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Erasca Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.